Results 71 to 80 of about 4,142 (167)

Long‐Term Effect of 2 Years of Persistent Guselkumab Therapy on Disease Severity and Patient‐Reported Outcomes in the CorEvitas Psoriasis Registry

Dermatologic Therapy
Background Guselkumab, an IL‐23 inhibitor, improved disease activity through five years in clinical trials of patients with moderate to severe plaque psoriasis.
Bruce E. Strober, April W. Armstrong, Timothy Fitzgerald, Katelyn Rowland, Olivia Choi, Daphne Chan, Jud C. Janak, Maya Marchese, Rachel E. Teneralli, Hyung-Joo Kang, Alvin H. Li, Steven R. Feldman   +11 more
doaj   +1 more source

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment

Journal of Inflammation Research
Xiuqing Yuan,1,* Tiantian Xin,1,* Huanhuan Yu,1 Jian Huang,2 Yaohan Xu,1 Caixin Ou,1 Yongfeng Chen1 1Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China ...
Yuan X, Xin T, Yu H, Huang J, Xu Y, Ou C, Chen Y   +6 more
doaj  

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

Rheumatology and Therapy
Introduction Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a “real-life” multicentre patient cohort.
Piero Ruscitti, Giulia Cataldi, Martina Gentile, Alice Dionisi, Paola Volpe, Annacarla Finucci, Lucrezia Verardi, Claudia Di Muzio, Noemi Italiano, Eleonora Celletti, Myriam Di Penta, Ilenia Di Cola, Alessandra Marrelli, Alessia Alfonsi, Francesco Delle Monache, Francesco Cipollone, Marco Gabini, Paola Cipriani   +17 more
doaj   +1 more source

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome

Turkderm Turkish Archives of Dermatology and Venereology
In this case report, we present a 29-year-old patient with Down syndrome (DS) who manifested both psoriasis and hidradenitis suppurativa (HS) concurrently.
Simge Ünal, Tuğcan Yüksek
doaj   +1 more source

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)

Dermatology and Therapy
Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Paolo Dapavo, Piergiorgio Malagoli, Angelo V. Marzano, Francesco Loconsole, Martina Burlando, Anna Balato, Valentina Dini, Matteo Megna, Giampiero Girolomoni, Emanuele Trovato, Claudia Lasagni, Massimo Travaglini, Claudio Guarneri, Nicola Zerbinati, Simone Ribero, Francesca M. Gaiani, Carlo G. Carrera, Emanuele C. Cozzani, Eugenia V. Di Brizzi, Alessandra Michelucci, Luca Potestio, Martina Maurelli, Martina Dragotto, Luca Mastorino, Eleonora Bongiovanni, Francesco Messina, Andrea Sechi, Rossana Moroni, Antonio Costanzo, Alessandra Narcisi   +32 more
doaj   +1 more source

Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials

Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a heterogeneous disease, and clinical manifestations can differ between sexes. Sex-disaggregated baseline characteristics, guselkumab efficacy, and radiographic progression were assessed in a pooled cohort of ...
Dafna D. Gladman, Lihi Eder, Carlo Selmi, Philip J. Mease, Alexis Ogdie, Karissa Lozenski, Elizabeth Adamson, Mohamed Sharaf, Emmanouil Rampakakis, Laura Pina Vegas, Laura C. Coates   +10 more
doaj   +1 more source

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Rheumatology and Therapy
Introduction The aim of this study was to evaluate guselkumab efficacy through week 100 in participants with psoriatic arthritis (PsA) and severe disease activity or patient global assessment (PtGA).
Christopher T. Ritchlin, Ennio Lubrano, Maria Sole Chimenti, Evan Leibowitz, Mohamed Sharaf, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Atul Deodhar   +8 more
doaj   +1 more source

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials

Rheumatology and Therapy
Introduction There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1 and -2, and ...
Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, Atul Deodhar   +8 more
doaj   +1 more source

Guselkumab (Tremfya) [PDF]

Dermatologie pro praxi, 2020
Jan Hugo, Spyridon Gkalpakiotis
openaire   +1 more source

Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis. [PDF]

ACG Case Rep J
Moghe R, Mathew AJ, Choi D, Rubin DT.
europepmc   +1 more source